Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers
Sponsor: Food and Drug Administration (FDA)
A observational or N/A phase clinical study on Habits and Influenza, Human, this trial is completed. The trial is conducted by Food and Drug Administration (FDA) and has accumulated 10 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
Status: Recruiting → Completed
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Food and Drug Administration (FDA)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health (NIH)
- Tobacco Centers of Regulatory Science (TCORS
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .